Table 5 Prospective studies of bone mineral density (BMD) during androgen deprivation therapy (ADT).
Country | Stage | n | Type of ADT | Change in BMD | |
|---|---|---|---|---|---|
Australia14 | M1 | 12 | CAB | −6.6% at 6 mo | L spine |
Sweden15 | M0 | 11 | Orchiectomy | −10% at 12 mo | Proximal femur |
France16 | M0 | 12 | GnRH agonist | −4.6% at 12 mo −3.9% at 12 mo | L spine Femoral neck |
USA17 | M0 | 10 16 | Orchiectomy GnRH agonist or CAB | −2.4% at 12 mo −3.4% at 12 mo | Femoral neck |
USA18 | M0 | 15 | GnRH agonist | −2.8% at 12 mo | spine |
Australia19 | M0 | 26 | GnRH agonist | −3.9% at 12 mo | L spine |
USA20 | M0 | 22 | CAB | −3.3% at 12 mo | L spine |
Italy21 | M0 | 35 | GnRH agonist | −2.3% at 12 mo | L spine |
Spain22 | M0 | 31 | GnRH agonist | −4.8% at 12 mo | L spine |
Australia23 | M0 | 72 | CAB | −1.9% at 9 mo −3.3% at 9 mo | Hip spine |
Present study | M0 & M1 | 234 70 | CAB GnRH agonist | −2.6% at 12 mo −4.4% at 12 mo | L spine L spine |
